Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Incyte Corporation
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Maxia Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.